Lipid-protamine-DNA-mediated antigen delivery.
Curr Drug Deliv
; 2(4): 401-6, 2005 Oct.
Article
en En
| MEDLINE
| ID: mdl-16305443
The development of novel 'new generation' vaccine systems that is based on proteins, peptides or DNA is of great current interest. However, due to the lower efficiencies of these new generation vaccines, they are seldomly used alone. Rather, their formulations often contain adjuvants, either to enhance the immune responses or to reduce dosing. The present chapter will provide a brief overview of the recent advances in peptide-based cancer vaccine adjuvants, focusing mainly on Liposome-Protamine-DNA (LPD) nanoparticle-mediated antigen delivery.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
ADN
/
Protaminas
/
Sistemas de Liberación de Medicamentos
/
Vacunas de ADN
/
Lípidos
/
Antígenos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Drug Deliv
Asunto de la revista:
FARMACIA
/
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Emiratos Árabes Unidos